Pharming Group (ENXTAM:PHARM) - Stock Price, News & Analysis

PHARM Stock Overview

PHARM fundamental analysis
Snowflake Score
Valuation	5/6
Future Growth	4/6
Past Performance	0/6
Financial Health	6/6
Dividends	0/6

Rewards

Trading at 80.9% below our estimate of its fair value

Earnings are forecast to grow 52.89% per year

Analysts in good agreement that stock price will rise by 122.2%

Risk Analysis

Shareholders have been diluted in the past year

Pharming Group N.V. Competitors

Galapagos

ENXTAM:GLPG

€1.8b

Intercept Pharmaceuticals

NasdaqGS:ICPT

US$794.7m

TaiMed Biologics

TPEX:4147

NT$20.7b

PureTech Health

LSE:PRTC

UK£555.3m

Price History & Performance

Summary of all time highs, changes and price drops for Pharming Group
Historical stock prices
Current Share Price	€0.90
52 Week High	€1.31
52 Week Low	€0.86
Beta	0.73
1 Month Change	-13.63%
3 Month Change	-20.42%
1 Year Change	-9.18%
3 Year Change	-17.01%
5 Year Change	7.53%
Change since IPO	-99.05%

Revenues Working Against Pharming Group N.V.'s (AMS:PHARM) Share Price

Feb 14

Recent updates

Revenues Working Against Pharming Group N.V.'s (AMS:PHARM) Share Price

Feb 14

Health Check: How Prudently Does Pharming Group (AMS:PHARM) Use Debt?

Nov 11

Pharming Group N.V. (AMS:PHARM) Shares Could Be 49% Below Their Intrinsic Value Estimate

Aug 23

Health Check: How Prudently Does Pharming Group (AMS:PHARM) Use Debt?

Jun 20

Is Pharming Group (AMS:PHARM) Using Too Much Debt?

Mar 16

Pharming Group N.V.'s (AMS:PHARM) Intrinsic Value Is Potentially 41% Above Its Share Price

Feb 17

We Think Pharming Group (AMS:PHARM) Can Manage Its Debt With Ease

Dec 08

Is Pharming Group (AMS:PHARM) Using Too Much Debt?

Aug 05

Pharming Group N.V. Just Missed EPS By 56%: Here's What Analysts Think Will Happen Next

Mar 21

These Analysts Think Pharming Group N.V.'s (AMS:PHARM) Sales Are Under Threat

Mar 19

Is Pharming Group (AMS:PHARM) Using Too Much Debt?

Feb 20

Pharming Group N.V.'s (AMS:PHARM) Intrinsic Value Is Potentially 40% Above Its Share Price

Oct 29

Pharming Group (AMS:PHARM) Seems To Use Debt Quite Sensibly

Jun 03

Increases to CEO Compensation Might Be Put On Hold For Now at Pharming Group N.V. (AMS:PHARM)

May 12

Is Pharming Group N.V.'s (AMS:PHARM) Recent Performance Tethered To Its Attractive Financial Prospects?

Mar 15

Pharming Group (AMS:PHARM) Seems To Use Debt Rather Sparingly

Feb 15

Shareholder Returns

	PHARM	NL Biotechs	NL Market
7D	-8.9%	-3.1%	-4.3%
1Y	-9.2%	-14.1%	13.8%

Return vs Industry: PHARM exceeded the Dutch Biotechs industry which returned -14.1% over the past year.

Return vs Market: PHARM underperformed the Dutch Market which returned 13.8% over the past year.

Price Volatility

Is PHARM's price volatile compared to industry and market?
PHARM volatility
PHARM Average Weekly Movement	4.8%
Biotechs Industry Average Movement	7.5%
Market Average Movement	3.7%
10% most volatile stocks in NL Market	7.5%
10% least volatile stocks in NL Market	2.2%

Stable Share Price: PHARM's share price has been volatile over the past 3 months.

Volatility Over Time: PHARM's weekly volatility (5%) has been stable over the past year.

About the Company

Founded	Employees	CEO	Website
1988	382	Simon de Vries	www.pharming.com

Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome.

Pharming Group N.V. Fundamentals Summary

How do Pharming Group's earnings and revenue compare to its market cap?
PHARM fundamental statistics
Market cap	€606.09m
Earnings (TTM)	-€9.90m
Revenue (TTM)	€230.30m

2.6x

P/S Ratio

-61.2x

P/E Ratio

Is PHARM overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
PHARM income statement (TTM)
Revenue	US$245.32m
Cost of Revenue	US$25.21m
Gross Profit	US$220.10m
Other Expenses	US$230.65m
Earnings	-US$10.55m

Last Reported Earnings

Dec 31, 2023

Next Earnings Date

May 08, 2024

Earnings per share (EPS)	-0.016
Gross Margin	89.72%
Net Profit Margin	-4.30%
Debt/Equity Ratio	63.3%

How did PHARM perform over the long term?

See historical performance and comparison

PHARM Stock Overview

Rewards

Risk Analysis

Pharming Group N.V. Competitors

ENXTAM:GLPG

€1.8b

NasdaqGS:ICPT

US$794.7m

TPEX:4147

NT$20.7b

LSE:PRTC

UK£555.3m

Price History & Performance

Recent News & Updates

Pharming Group N.V. announced that it expects to receive €100 million in funding

Price target increased by 11% to €2.00

Full year 2023 earnings released: US$0.015 loss per share (vs US$0.021 profit in FY 2022)

Pharming Group N.V. to Report Q2, 2024 Results on Aug 01, 2024

Revenues Working Against Pharming Group N.V.'s (AMS:PHARM) Share Price

Consensus estimates of losses per share improve by 31%

Recent updates

Pharming Group N.V. announced that it expects to receive €100 million in funding

Price target increased by 11% to €2.00

Full year 2023 earnings released: US$0.015 loss per share (vs US$0.021 profit in FY 2022)

Pharming Group N.V. to Report Q2, 2024 Results on Aug 01, 2024

Revenues Working Against Pharming Group N.V.'s (AMS:PHARM) Share Price

Consensus estimates of losses per share improve by 31%

Pharming Group N.V. to Report Q4, 2023 Results on Mar 14, 2024

Health Check: How Prudently Does Pharming Group (AMS:PHARM) Use Debt?

Consensus EPS estimates upgraded to US$0.014 loss, revenue downgraded

Consensus estimates of losses per share improve by 34%

New minor risk - Shareholder dilution

Third quarter 2023 earnings released: EPS: US$0.005 (vs US$0.014 in 3Q 2022)

Pharming Group N.V. Appoints Richard Peters as Non-Executive Director

Pharming Group N.V. (AMS:PHARM) Shares Could Be 49% Below Their Intrinsic Value Estimate

Consensus EPS estimates fall by 140%

Pharming Group N.V. Announces First Patient Enrolled in Phase Iii Clinical Trial of Leniolisib for the Treatment of Apds in Japan

First half 2023 earnings released: US$0.017 loss per share (vs US$0.03 profit in 1H 2022)

Pharming Group N.V. Appoints Alexander Breidenbach as Chief Business Officer

Now 20% undervalued

Health Check: How Prudently Does Pharming Group (AMS:PHARM) Use Debt?

Pharming Group N.V. Approves the Proposal to Reappoint Paul Sekhri, Chair of the Board, as Non-Executive Director for A Period of One Year Who Will Resign from the Board Upon Appointment of His Successor

Investor sentiment improves as stock rises 15%

Price target increased by 8.9% to €1.83

Investor sentiment improves as stock rises 18%

Full year 2022 earnings released: EPS: US$0.021 (vs US$0.025 in FY 2021)

Is Pharming Group (AMS:PHARM) Using Too Much Debt?

Pharming Group N.V. Provides Update on EMA Regulatory Review of Leniolisib for Apds in Europe

Pharming Group N.V.'s (AMS:PHARM) Intrinsic Value Is Potentially 41% Above Its Share Price

Now 20% undervalued

Now 20% undervalued

Investor sentiment improved over the past week

Pharming Group N.V. Announces Positive Interim Analysis Data from Open-Label Extension Study of Leniolisib in Presentation At the 64Th American Society of Hematology (ASH) Annual Meeting and Exposition

Pharming Group N.V. to Report Fiscal Year 2022 Results on Mar 16, 2023

Pharming Group N.V. Announces Positive Results of Phase 3 Clinical Trial of Investigational Drug Leniolisib

We Think Pharming Group (AMS:PHARM) Can Manage Its Debt With Ease

High number of new directors

Investor sentiment improved over the past week

Pharming Group N.V. Announces European Medicines Agency Validates its Marketing Authorisation Application Under Accelerated Assessment for Leniolisib

Third quarter 2022 earnings: EPS exceeds analyst expectations

Pharming Group N.V. Submits Marketing Authorisation Application to European Medicines Agency for Leniolisib

Price target increased to €13.52

Pharming Group N.V. Announces US FDA Acceptance for Priority Review of its New Drug Application for Leniolisib

Second quarter 2022 earnings released: EPS: US$0.025 (vs US$0.009 in 2Q 2021)

Is Pharming Group (AMS:PHARM) Using Too Much Debt?

Pharming Announces New ICD-10-CM Code for APDS, a Rare Primary Immunodeficiency

Pharming Group N.V. Receives Accelerated Assessment in Europe for Leniolisib for the Treatment of Rare Immunodeficiency, APDS

Consensus forecasts updated

First quarter 2022 earnings: EPS misses analyst expectations

GIMV NV (ENXTBR:GIMB) completed the acquisition of 20.87% stake in Bioconnection B.V. from Pharming Group N.V. (ENXTAM:PHARM).

High number of new directors

Pharming Receives Agreement of Paediatric Investigation Plan and Promising Innovative Medicine Designation for Leniolisib from UK MHRA

GIMV NV (ENXTBR:GIMB) reached an agreement to acquire 20.87% stake in Bioconnection B.V. from Pharming Group N.V. (ENXTAM:PHARM) for ?6.9 million.

Pharming Group N.V. Announces Positive Data from Phase II/III Leniolisib Trial Presented at Clinical Immunology Society 2022 Annual Meeting

Consensus revenue estimates fall by 14%

Pharming Group N.V. Just Missed EPS By 56%: Here's What Analysts Think Will Happen Next

These Analysts Think Pharming Group N.V.'s (AMS:PHARM) Sales Are Under Threat

Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behind

Price target decreased to €1.80

Is Pharming Group (AMS:PHARM) Using Too Much Debt?